en · de · es · pt
epitalon-notes.peptides3626.com › News › Structure, Naming And Discovery — Beginner to Advanced

Structure, Naming And Discovery — Beginner to Advanced

By Editorial Desk · published 2025-09-21 · last reviewed 2025-11-13 · News

AEDG is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.

Structure, Naming and Discovery

Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.

Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.

The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.

Epitalon Background And Identification

Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.

The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.

Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.

Epitalon at a glance

PropertyValueNotes
Molecular formulaC14H22N4O9Derived from the four constituent residues
Molecular massAbout 390.35 DaMonoisotopic value, confirmed by mass spectrometry
Residue sequenceAla-Glu-Asp-GlyRead from the N-terminus to the C-terminus
Common synonymsEpithalon; AEDGBoth forms appear in reference catalogues
Net charge near neutral pHNegativeTwo acidic side chains give a low isoelectric point

Peptide Identity and Laboratory Handling

Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.

Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.

Related pages on this site

Background and Chemical Identity

Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.

Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.

Peptide Identity and Research Origin

Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.

Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.

The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.

Epitalon Background and Discovery

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Supporting material

Affimer molecules, also known as adhiron, are small proteins that bind to target proteins with affinity in the nanomolar range. These engineered non-antibody binding proteins are designed to mimic the molecular recognition characteristics of monoclonal antibodies in different applications. These affinity reagents have been optimized to increase their stability, make them tolerant to a range of temperatures and pH, reduce their size, and to increase their expression in E.coli and mammalian cells.

Technologies based upon the polymerase chain reaction (PCR) method will become nearly ubiquitous gold standards of diagnostics of the near future, for several reasons. First, the catalog of infectious agents has grown to the point that virtually all of the significant infectious agents of the human population have been identified. Second, an infectious agent must grow within the human body to cause disease; essentially it must amplify its own nucleic acids to cause a disease. This amplification of nucleic acid in infected tissue offers an opportunity to detect the infectious agent by using PCR. Third, the essential tools for directing PCR, primers, are derived from the genomes of infectious agents, and with time those genomes will be known if they are not already. Thus, the technological ability to detect any infectious agent rapidly and specifically is currently available. The only remaining blockades to the use of PCR as a standard tool of diagnosis are in its cost and application, neither of which is insurmountable. The diagnosis of a few diseases will not benefit from the development of PCR methods, such as some of the clostridial diseases (tetanus and botulism). These diseases are fundamentally biological poisonings by relatively small numbers of infectious bacteria that produce extremely potent neurotoxins. A significant proliferation of the infectious agent does not occur, which limits the ability of PCR to detect the presence of any bacteria.

=== 31 May === One person was killed by Russian shelling in Vovchansk Raion in Kharkiv Oblast, while three people, including two children, were injured by Russian shelling in Kherson Oblast. One person was also killed by Russian shelling in Donetsk Oblast. Officials in the Russian-installed Luhansk People's Republic said that five people were killed and 19 others were injured after Ukrainian artillery hit a poultry farm. The State Border Guard Service of Ukraine reported that Russian troops had blown up a road that links Ukraine's Chernihiv Oblast with Russia's Bryansk Oblast, saying that the incident occurred at the tripoint between Ukraine, Russia and Belarus. Ukraine claimed that Russian-installed officials in occupied Luhansk were threatening to withhold the wages of workers who refused to open accounts at Russian banks. The Russian defence ministry claimed its forces had pushed out Ukrainian forces from positions around Krasnohorivka and Yasynuvata in Donetsk Oblast. A fire broke out at the Afipsky oil refinery in Russia's Krasnodar Krai. Veniamin Kondratyev, Governor of the region, blamed the fire on a Ukrainian drone strike. The fire was put out with minimal damage and no casualties. Another drone was reported to have crashed into the Ilsky refinery. The governor of Belgorod Oblast announced the beginning of evacuations of children from areas affected by Ukrainian shelling, saying that 300 children would be taken to Voronezh, about 250 km (160 mi) away, while another 1,000 children would be evacuated to other regions over the coming days.

GlcA = β-D-glucuronic acid, IdoA = α-L-iduronic acid, IdoA(2S) = 2-O-sulfo-α-L-iduronic acid, GlcNAc = 2-deoxy-2-acetamido-α-D-glucopyranosyl, GlcNS = 2-deoxy-2-sulfamido-α-D-glucopyranosyl, GlcNS(6S) = 2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-O-sulfate One unit of heparin (the "Howell unit") is an amount approximately equivalent to 0.002 mg of pure heparin, which is the quantity required to keep 1 ml of cat's blood fluid for 24 hours at 0 °C.

== See also == List of antidepressants Serotonin modulator and stimulator (SMS) Noradrenergic and specific serotonergic antidepressant (NaSSA) Norepinephrine-dopamine disinhibitor (NDDI) Selective serotonin reuptake inhibitor (SSRI) DSP-6745

Sources: en.wikipedia.org

Notes from published material

As examples, Moderna's RNA vaccine candidate requires cold chain management just above freezing temperatures between 2 and 8 °C (36 and 46 °F) with limited storage duration (30 days), but the Pfizer-BioNTech RNA candidate requires storage between −80 and −60 °C (−112 and −76 °F), or colder throughout deployment until vaccination. In February 2021, Pfizer and BioNTech asked the U.S. Food and Drug Administration (FDA) to update the emergency use authorization (EUA) to permit the vaccine to be stored at between −25 and −15 °C (−13 and 5 °F) for up to two weeks before use. As of May 2021, Walvax is conducting Phase III trials for its mRNA vaccine which could be stored at room temperature for six months. After a vaccine vial is punctured to administer a dose, it is viable for only six hours, then must be discarded, requiring attention to local management of cold storage and vaccination processes. Because the COVID‑19 vaccine will likely be in short supply for many locations during early deployment, vaccination staff will have to avoid spoilage and waste, which typically are as much as 30% of the supply. The cold chain is further challenged by the type of local transportation for the vaccines in rural communities, such as by motorcycle or delivery drone, need for booster doses, use of diluents, and access to vulnerable populations, such as healthcare staff, children and the elderly.

=== Mental illness referred to in children's television === A 2000 study of New Zealand Children's television shows showed that a mental illness reference appeared in 59 out of 128 episodes chosen. In those 59 episodes, there were 159 references to mental illness, frequently of character descriptions. The terms "mad," "crazy," and "losing your mind" were above the three most common references. Character appearances consisted of disfigured facial features (teeth, noses, etc.) and disfigured extremities. Mental illness has also been portrayed in Walt Disney animated films. A study examined the portrayal of mental illness in Disney films and found that 85% of these films made reference to mental illness, and 21% of the characters were referred to as mentally ill. On average, 4.6 references to mental illness were made in these films, with the most commonly used terms being "mad," "crazy," or "nutty." The study highlighted how Maurice, from Beauty and the Beast, was often depicted as mentally ill, referred to as a lunatic, and was even attempted to be sent to an asylum. Another study examined 40 children's programs on Netflix, analyzing 339 episodes for references to mental illness. The study found that 23 of these programs had at least one reference to mental illness, with 58 episodes featuring such references. It also noted differences in how male and female characters with mental illness were portrayed. Male characters were often depicted as violent or aggressive, while female characters were shown as "crazy" or obsessive.

For shelter, the Komodo dragon digs holes that can measure from 1 to 3 m (3.3 to 9.8 ft) wide with its powerful forelimbs and claws. Because of its large size and habit of sleeping in these burrows, it is able to conserve body heat throughout the night and minimise its basking period the morning after. The Komodo dragon stays in the shade during the hottest part of the day and hunts in the afternoon. These special resting places, usually located on ridges with cool sea breezes, are marked with droppings and are cleared of vegetation. They serve as strategic locations from which to ambush deer.

Quinolinate synthase (EC 2.5.1.72, NadA, QS, quinolinate synthetase) is an enzyme with systematic name glycerone phosphate:iminosuccinate alkyltransferase (cyclizing). This enzyme catalyses the following chemical reaction

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.

Are epitalon and epithalon different compounds?

No. The two spellings refer to the same tetrapeptide, and the difference reflects transliteration from Russian. Laboratories and catalogues use both forms interchangeably. The material is also indexed as AEDG, taken from the one-letter codes of its residues.

How does epitalon differ from epithalamin?

Epithalamin is a mixed preparation derived from animal pineal tissue and contains many peptides. Epitalon is one synthetic sequence chosen for study from that broader mixture. Statements about one do not transfer directly to the other.

What is epitalon derived from?

It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.

Network